Licensing a potential first-in-class, anti-IL-17 and anti-BAFF dual antagonist In connection with the transaction, Zura Bio announces pricing of $80 million private placement financing SAN DIEGO --(BUSINESS WIRE)--Apr. 27, 2023-- Zura Bio Limited (Nasdaq: “ZURA”) (“Zura” or “Zura Bio”), a
SAN DIEGO --(BUSINESS WIRE)--Apr. 14, 2023-- Zura Bio Limited (Nasdaq: “ZURA”) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the appointment of Michael D.
SAN DIEGO --(BUSINESS WIRE)--Mar. 27, 2023-- As previously announced on March 21, 2023 , Zura Bio Limited (“Zura”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, announced the closing of its business combination with
Zura Bio Limited to trade on Nasdaq as a clinical-stage biotechnology company focused on immunology Business combination results in approximately $65 million in gross cash proceeds to support research and development initiatives and potential future acquisitions Combined company to trade on Nasdaq
LONDON--( BUSINESS WIRE )--JATT Acquisition Corp (NYSE: JATT) (“JATT”), a publicly traded special purpose acquisition company, today announced that its shareholders voted to approve its proposed business combination with Zura Bio Limited (“Zura”), a clinical-stage biotechnology company.
LONDON--( BUSINESS WIRE )--JATT Acquisition Corp (NYSE: JATT, JATT.WS and JATT.U) (the "Company"), a publicly-traded special purpose acquisition company, today announced that it will voluntarily transfer the listing of its Class A ordinary shares, public warrants and units from the New York Stock
Record date of Feb 26 th 2023 established as well as; Extraordinary general meeting of shareholders to approve the Business Combination set for March 16 th 2023 March 02, 2023 07:02 AM Eastern Standard Time LONDON--( BUSINESS WIRE )--JATT Acquisition Corp (NYSE: “JATT”), the publicly traded